Elizabeth Selvin1, Mariana Lazo2, Yuan Chen2, Lu Shen2, Jonathan Rubin2, John W McEvoy2, Ron C Hoogeveen2, A Richey Sharrett2, Christie M Ballantyne2, Josef Coresh2. 1. From the Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., M.L., Y.C., L.S., J.W.M., A.R.S., J.C.); Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD (E.S., M.L., J.R., J.C.); Department of Medicine, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX (R.C.H., C.M.B.). eselvin@jhu.edu. 2. From the Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., M.L., Y.C., L.S., J.W.M., A.R.S., J.C.); Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD (E.S., M.L., J.R., J.C.); Department of Medicine, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX (R.C.H., C.M.B.).
Abstract
BACKGROUND: Persons with prediabetes and diabetes mellitus are at high risk for cardiovascular events. However, the relationships of prediabetes and diabetes mellitus to the development of subclinical myocardial damage are unclear. METHODS AND RESULTS: We measured cardiac troponin T with a highly sensitive assay (hs-cTnT) at 2 time points, 6 years apart, among 9051 participants of the community-based Atherosclerosis Risk in Communities Study with no diabetes mellitus, or prediabetes, and without cardiovascular disease including silent myocardial infarction by ECG. First, we examined the incidence of elevated hs-cTnT (≥14 ng/L) at 6 years of follow-up. Second, we examined clinical outcomes during the subsequent ≈14 years of follow-up among persons with and without incident elevations in hs-cTnT. Cumulative probabilities of elevated hs-cTnT at 6 years among persons with no diabetes mellitus, prediabetes, and diabetes mellitus were 3.7%, 6.4%, and 10.8%, respectively. Compared with normoglycemic persons, the adjusted relative risks for incident elevated hs-cTnT were 1.40 (95% CI, 1.08-1.80) for prediabetes and 2.47 (95% CI, 1.78-3.43) for diabetes mellitus. Persons with diabetes mellitus and incident elevations in hs-cTnT were at a substantially higher risk of heart failure (hazard ratio, 6.37 [95% CI, 4.27-9.51]), death (hazard ratio, 4.36 [95% CI, 3.14-6.07]), and coronary heart disease (hazard ratio, 3.84 [95% CI, 2.52-5.84]) compared with persons without diabetes mellitus and no incident elevation in hs-cTnT. CONCLUSIONS: Prediabetes and diabetes mellitus were independently associated with the development of subclinical myocardial damage, as assessed by hs-cTnT, and those persons with evidence of subclinical damage were at highest risk for clinical events. These results support a possible deleterious effect of hyperglycemia on the myocardium, possibly reflecting a microvascular cause.
BACKGROUND:Persons with prediabetes and diabetes mellitus are at high risk for cardiovascular events. However, the relationships of prediabetes and diabetes mellitus to the development of subclinical myocardial damage are unclear. METHODS AND RESULTS: We measured cardiac troponin T with a highly sensitive assay (hs-cTnT) at 2 time points, 6 years apart, among 9051 participants of the community-based Atherosclerosis Risk in Communities Study with no diabetes mellitus, or prediabetes, and without cardiovascular disease including silent myocardial infarction by ECG. First, we examined the incidence of elevated hs-cTnT (≥14 ng/L) at 6 years of follow-up. Second, we examined clinical outcomes during the subsequent ≈14 years of follow-up among persons with and without incident elevations in hs-cTnT. Cumulative probabilities of elevated hs-cTnT at 6 years among persons with no diabetes mellitus, prediabetes, and diabetes mellitus were 3.7%, 6.4%, and 10.8%, respectively. Compared with normoglycemic persons, the adjusted relative risks for incident elevated hs-cTnT were 1.40 (95% CI, 1.08-1.80) for prediabetes and 2.47 (95% CI, 1.78-3.43) for diabetes mellitus. Persons with diabetes mellitus and incident elevations in hs-cTnT were at a substantially higher risk of heart failure (hazard ratio, 6.37 [95% CI, 4.27-9.51]), death (hazard ratio, 4.36 [95% CI, 3.14-6.07]), and coronary heart disease (hazard ratio, 3.84 [95% CI, 2.52-5.84]) compared with persons without diabetes mellitus and no incident elevation in hs-cTnT. CONCLUSIONS:Prediabetes and diabetes mellitus were independently associated with the development of subclinical myocardial damage, as assessed by hs-cTnT, and those persons with evidence of subclinical damage were at highest risk for clinical events. These results support a possible deleterious effect of hyperglycemia on the myocardium, possibly reflecting a microvascular cause.
Authors: Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski Journal: N Engl J Med Date: 2013-06-24 Impact factor: 91.245
Authors: Wenhui Zhao; Peter T Katzmarzyk; Ronald Horswell; Yujie Wang; Jolene Johnson; Gang Hu Journal: J Clin Endocrinol Metab Date: 2013-01-01 Impact factor: 5.958
Authors: Aaron R Folsom; Vijay Nambi; Elizabeth J Bell; Oludamilola W Oluleye; Rebecca F Gottesman; Pamela L Lutsey; Rachel R Huxley; Christie M Ballantyne Journal: Stroke Date: 2013-03-07 Impact factor: 7.914
Authors: M Odette Gore; Stephen L Seliger; Christopher R Defilippi; Vijay Nambi; Robert H Christenson; Ibrahim A Hashim; Ron C Hoogeveen; Colby R Ayers; Wensheng Sun; Darren K McGuire; Christie M Ballantyne; James A de Lemos Journal: J Am Coll Cardiol Date: 2014-02-12 Impact factor: 24.094
Authors: Elizabeth Selvin; Andreea M Rawlings; Richard M Bergenstal; Josef Coresh; Frederick L Brancati Journal: Diabetes Care Date: 2013-05-30 Impact factor: 19.112
Authors: John W McEvoy; Yuan Chen; Chiadi E Ndumele; Scott D Solomon; Vijay Nambi; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin Journal: JAMA Cardiol Date: 2016-08-01 Impact factor: 14.676
Authors: John W McEvoy; Yuan Chen; Vijay Nambi; Christie M Ballantyne; A Richey Sharrett; Lawrence J Appel; Wendy S Post; Roger S Blumenthal; Kunihiro Matsushita; Elizabeth Selvin Journal: Circulation Date: 2015-07-07 Impact factor: 29.690
Authors: James L Januzzi; Umesh Sharma; Pearl Zakroysky; Quynh A Truong; Pamela K Woodard; J Hector Pope; Thomas Hauser; Thomas Mayrhofer; J Toby Nagurney; David Schoenfeld; W Frank Peacock; Jerome L Fleg; Stephen Wiviott; Peter S Pang; James Udelson; Udo Hoffmann Journal: Am Heart J Date: 2015-01-09 Impact factor: 4.749
Authors: Giovane R Sousa; David Pober; Alfonso Galderisi; HuiJuan Lv; Liping Yu; Alexandre C Pereira; Alessandro Doria; Mikhail Kosiborod; Myra A Lipes Journal: Circulation Date: 2019-02-05 Impact factor: 29.690
Authors: Yashashwi Pokharel; Wensheng Sun; Dennis T Villareal; Elizabeth Selvin; Salim S Virani; Chiadi E Ndumele; Ron C Hoogeveen; Josef Coresh; Eric Boerwinkle; Kenneth R Butler; Scott D Solomon; James S Pankow; Biykem Bozkurt; Christie M Ballantyne; Vijay Nambi Journal: Eur J Prev Cardiol Date: 2016-12-12 Impact factor: 7.804
Authors: Caitlin W Hicks; Dan Wang; Natalie R Daya; B Gwen Windham; Christie M Ballantyne; Kunihiro Matsushita; Elizabeth Selvin Journal: Clin Chem Date: 2020-05-01 Impact factor: 8.327